Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MMP13 | P45452 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12237260 | 0.86 | KMT2A (0.56) | KMT2AMEN1L3MBTL1HPGDPOLB | |
| SCHEMBL29072741 | 0.86 | KMT2A (0.55) | KMT2AMEN1L3MBTL1HPGDHTT | |
| SCHEMBL29072732 | 0.86 | KMT2A (0.55) | KMT2AMEN1L3MBTL1HPGDHTT | |
| SCHEMBL12237256 | 0.85 | KMT2A (0.49) | KMT2AMEN1MAPK1POLBALDH1A1 | |
| SCHEMBL12259462 | 0.83 | MMP13 (0.48) | KMT2AMEN1L3MBTL1HTTSMN1; SMN2 | |
| SCHEMBL12259458 | 0.80 | MMP13 (0.45) | KMT2AMEN1L3MBTL1HTTSMN1; SMN2 | |
| SCHEMBL9550606 | 0.79 | KMT2A (0.62) | KMT2AMEN1L3MBTL1HPGDHTT | |
| SCHEMBL12259812 | 0.79 | MMP13 (0.58) | KMT2AMEN1HTTMMP13MMP1 | |
| SCHEMBL13567495 | 0.79 | KMT2A (0.50) | KMT2AMEN1L3MBTL1HPGDMAPK1 | |
| SCHEMBL13567536 | 0.79 | KMT2A (0.53) | KMT2AMEN1L3MBTL1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9387254-B2 | Prodrugs and drug-macromolecule conjugates having controlled drug release rates | PROLYNX LLC (US) | 2016-07-12 | — | — | US | disclosed |
| US-9387254-B2 | Prodrugs and drug-macromolecule conjugates having controlled drug release rates | PROLYNX LLC (US) | 2016-07-12 | — | — | US | disclosed |
| US-20140296476-A1 | PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES | PROLYNX LLC | 2014-10-02 | — | — | US | disclosed |
| US-20140296476-A1 | PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES | PROLYNX LLC | 2014-10-02 | — | — | US | disclosed |
| US-8680315-B2 | Prodrugs and drug-macromolecule conjugates having controlled drug release rates | PROLYNX, LLC (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680315-B2 | Prodrugs and drug-macromolecule conjugates having controlled drug release rates | PROLYNX, LLC (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110263502-A1 | PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES | PROLYNX, LLC | 2011-10-27 | — | — | US | disclosed |
| US-20110263502-A1 | PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES | PROLYNX, LLC | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296476-A1 | PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES | ABCB1, ABCB11, DNPEP | KMT2A 3824/4885MEN1 805/4885L3MBTL1 4082/4885 |
| US-20110263502-A1 | PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES | ABCB1, ABCB11, DNPEP | KMT2A 3824/4885MEN1 805/4885L3MBTL1 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.